• 1
    Moore AS, Cotter SM, Rand WM, et al. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. J Vet Intern Med 2001;15:348354.
  • 2
    Garrett LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704709.
  • 3
    Simon D, Nolte I, Eberle N, et al. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol. J Vet Intern Med 2006;20:948954.
  • 4
    Carter RF, Harris CK, Withrow SJ, et al. Chemotherapy of canine lymphoma with histopathological correlation: Doxorubicine alone compared to COP as first treatment regimen. J Am Anim Hosp Assoc 1987;23:587596.
  • 5
    Sorenmo K, Overley B, Krick E, et al. Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases. Vet Comp Oncol 2010;8:196208.
  • 6
    Rassnick KM, Mauldin GE, Al-Sarraf R, et al. MOPP chemotherapy for treatment of resistant lymphoma in dogs: A retrospective study of 117 cases (1989–2000). J Vet Intern Med 2002;16:576580.
  • 7
    Moore AS, London CA, Wood CA, et al. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. J Vet Intern Med 1999;13:395398.
  • 8
    Alvarez FJ, Kisseberth WC, Gallant SL, et al. Dexamethazone, Melphalan, Actinomycin D, Cytosine Arabinoside (DMAC) protocol for dogs with relapsed lymphoma. J Vet Intern Med 2006;20:11781183.
  • 9
    Kern W, Schoch C, Haferlach T, et al. Monitoring of minimal residual disease in acute myeloid leukemia. Crit Rev Oncol Hematol 2005;56:283309.
  • 10
    Pott C, Schrader C, Gesk S, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006;107:22712278.
  • 11
    Bruggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006;107:11161123.
  • 12
    Rambaldi A, Lazzari M, Manzoni C, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002;99:856862.
  • 13
    Lane S, Saal R, Mollee P, et al. A ≥ 1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. Leukemia Lymphoma 2008;49:517523.
  • 14
    Mitterbauer M, Neumeister P, Kalhs P, et al. Long-term clinical and molecular remission after allogenic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma. Leukemia 2001;15:635641.
  • 15
    Uchiyama M, Maesawa C, Yahima A, et al. Development of consensus fluorogenically labeled probes of the immunoglobulin heavy-chain gene for detecting minimal residual disease in B-cell non-Hodgkin lymphomas. Cancer Sci 2003;94:877885.
  • 16
    Yashima A, Maesawa C, Uchiyama M, et al. Quantitative assessment of contaminating tumor cells in autologous peripheral blood stem cells of B-cell non-Hodgkin lymphomas using immunoglobulin heavy chain gene allele-specific oligonucleotide real-time quantitative-polymerase chain reaction. Leuk Res 2003;27:925934.
  • 17
    Yamazaki J, Baba K, Goto-Koshino Y, et al. Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction. Vet Immunol Immunopathol 2008;126:321331.
  • 18
    Yamazaki J, Takahashi M, Setoguchi A, et al. Monitoring of minimal residual disease (MRD) after multidrug chemotherapy and its correlation to outcome in dogs with lymphoma: A proof-of-concept study. J Vet Intern Med 2010;24:897903.
  • 19
    Fournel-Fleury C, Magnol JP, Bricaire P, et al. Cytohistological and immunological classification of canine malignant lymphomas: Comparison with human non-Hodgkin's lymphomas. J Comp Pathol 1997;117:3559.
  • 20
    Fournel-Fleury C, Ponce F, Felman P, et al. Canine T-cell lymphomas: A morphological, immunological, and clinical study of 46 new cases. Vet Pathol 2002;39:92109.
  • 21
    Burnett RC, Vernau W, Modiano JF, et al. Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes. Vet Pathol 2003;40:3241.
  • 22
    Tamura K, Yagihara H, Isotani M, et al. Development of the polymerase chain reaction assay based on the canine genome database for detection of monoclonality in B cell lymphoma. Vet Immunol Immunopathol 2006;110:163167.
  • 23
    Valli VE, Vernau W, de Lorimier LP, et al. Canine indolent nodular lymphoma. Vet Pathol 2006;43:241256.
  • 24
    Owen LN. TNM Classification of Tumours in Domestic Animals. Geneva: World Health Organization; 1980:4647.
  • 25
    Vail DM, Michels GM, Khanna C, et al. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)—A veterinary cooperative oncology group (VCOG) consensus document. Vet Comp Oncol 2010;8:2837.
  • 26
    Lana SE, Jackson TL, Burnett RC, et al. Utility of polymerase chain reaction for analysis of antigen receptor rearrangement in staging and predicting prognosis in dogs with lymphoma. J Vet Intern Med 2006;20:329334.
  • 27
    Doubek M, Brychtova Y, Berkovcova J, et al. Acute myeloid leukemias with recurrent genetic abnormalities: Frequent assessment of minimal residual disease and treatment of molecular relapse with chemotherapy. Leukemia 2005;19:885888.
  • 28
    Ladetto M, Magni M, Pagliano G, et al. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant 2006;12:12701276.